Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Over the last years a rising medical need for treatment of chronic pain was identified. Based
on previous findings indicating the pain modulating effects of cannabinoids in chronic pain
disorders, this clinical trial investigates the efficacy and tolerability of the THC-focused
nano endocannabinoid system modulator AP707 in patients with chronic back pain disorders.
Patients receive AP707 or placebo over the course of 14 weeks as an add-on to the standard of
care. Changes in pain intensity, quality of life and sleep and others measures are monitored
through different scales to assess the efficacy of AP707 in patients with chronic back pain.